Health Care News
-
Sanofi May Need to Bid Up to $21.3 Billion to Win Over Genzyme Investors
Sanofi-Aventis SA may have to pay at least $80 a share, or $21.3 billion, to acquire genetic-disease drugmaker Genzyme Corp. as activist directors drive up the price, investors in the U.S. biotechnology company say.
-
AstraZeneca Settlement Terms in Almost 4,000 Seroquel Cases to Stay Secret
AstraZeneca Plc , which tentatively settled almost 4,000 product-liability cases this month involving its antipsychotic drug Seroquel through mediation, said it will keep terms of the agreements confidential.
-
Geron Cleared By U.S. Regulators to Test Embryonic Stem-Cell Treatment
Geron Corp. said it was cleared by U.S. regulators to proceed with the first human test of an embryonic stem-cell therapy, aimed at patients with spinal-cord injuries. The shares rose 17 percent.
-
Charles River Withdraws $1.6 Billion Offer for WuXi
Charles River Laboratories International Inc. withdrew a $1.6 billion bid for WuXi PharmaTech (Cayman) Inc. , citing investor opposition to what would have been the largest foreign takeover of a China company.
More Health Care News
Advertisement
Ad Values
adType = "OAS";
Category = "03";
HCat = "x60";
Width = "300";
Height = "250";
Tile = "2";
Description =
Keys =
SiteForAd =
Healthcare ETFs
| SPDR-HEALTH CARE | 28.57 | 0.11 | 0.39 |
| ISHARES-NDQ BIOT | 81.03 | 1.35 | 1.69 |
| ISHARES-DJ HEALT | 58.86 | 0.15 | 0.26 |
| PHARMACEUT HOLDR | 60.01 | -0.18 | -0.30 |
| VANGUARD H/C ETF | 50.73 | 0.30 | 0.59 |

Rate this Page